If you'd like your company to be on this list please contact us
Select a name to see a detailed description, expert analysis and contact information.
|"DRRX intends to initiate a Phase 2 study with oral DUR-928 in PSC."|
|"As of Q3/17E, PMN had $3.3M in cash and zero debt on its balance sheet; we are maintaining our Speculative Buy rating."|
|"VIVE raised its outlook for 2017 revenues from $14M to $15–16M."|